A Novel ACVR2A::RAF1 Fusion in Spindle Cell Sarcoma
Genes, Chromosomes and Cancer · 2025-02 · 64 (2)
DOI: 10.1002/gcc.70033 ↗Kurz gefasst
Fallbericht in der Zeitschrift Genes, Chromosomes and Cancer, online erschienen am 14.02.2025. Verfasst von Anfeng Jiang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Xiangya Hospital, Central South University, Changsha, Hunan Province, China. Hauptthemen laut MEDLINE: Sarcoma, Oncogene Proteins, Fusion, Proto-Oncogene Proteins c-raf, Activin Receptors, Type II. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 20 Literaturangaben. Gefördert von: Natural Science Foundation of Hunan Province, 2022 Central South University Postgraduate Teaching Case Database Construction Project.
Abstract (Originalsprache)
Background
Kinase‐rearranged spindle cell sarcomas are characterized by unique molecular features. The advent of next‐generation sequencing (NGS) has enabled the detection of a multitude of kinase fusions, thereby contributing to the accurate categorization of these tumors. Case Presentation A 37‐year‐old woman experienced the fourth recurrence of a cranial base tumor 25 years following the initial surgery and radiation therapy. Histological analysis disclosed spindle‐shaped and oval tumor cells, along with a high number of mitotic figures. Immunohistochemistry showed a null immunophenotype, negative for pan‐TRK, S‐100, CD34, pan‐CK, GFAP, and Olig2. Molecular analysis of the tumor tissue identified a novel ACVR2A::RAF1 fusion, comprising the first four exons of ACVR2A and the last nine exons of RAF1. The resulting fusion protein retains the extracellular and transmembrane domains of ACVR2A, while its kinase domain is replaced by the kinase domain of RAF1. This hybrid protein likely contributes to tumorigenesis by activating RAF1 signaling in response to ACVR2A ligands from the TGF‐β superfamily. Treatment and Outcome The patient was treated with the MEK1 inhibitor Trametinib, 2 mg per time and once a day. One month later, MRI showed significant tumor shrinkage and pain relief.
Conclusion
The ACVR2A::RAF1 fusion represents a novel genomic profile in RAF1‐rearranged spindle cell sarcoma, offering a rational basis for targeted therapy. This case highlights the importance of molecular diagnostics in identifying actionable targets and guiding treatment, potentially leading to significant clinical benefits.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Oncology, Xiangya Hospital, Central South University, Changsha, Hunan Province, China.
- Advanced Molecular Pathology Institute of Soochow University and SANO, Suzhou, China.
- Suzhou Sano Precision Medicine Ltd, Suzhou, China.
- Department of Biological Sciences, Xi An Jiaotong-Liverpool University, Suzhou, China.
- Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Förderung
- Natural Science Foundation of Hunan Province
- 2022 Central South University Postgraduate Teaching Case Database Construction Project
Zitieren
APA
Jiang, A., Li, H., Li, D., Chen, H., Zhao, L., Zhang, Y., Li, Y., Rong, R., Li, B., & Xiao, S. (2025). A Novel ACVR2A::RAF1 Fusion in Spindle Cell Sarcoma. Genes, Chromosomes and Cancer, 64(2). https://doi.org/10.1002/gcc.70033
Vancouver
Jiang A, Li H, Li D, Chen H, Zhao L, Zhang Y, et al. A Novel ACVR2A::RAF1 Fusion in Spindle Cell Sarcoma. Genes, Chromosomes and Cancer. 2025;64(2). doi:10.1002/gcc.70033
BibTeX
@article{Jiang2025,
author = {Jiang, Anfeng and Li, Huan and Li, Dongbing and Chen, Huafei and Zhao, Lina and Zhang, Ying and Li, Yangyang and Rong, Rong and Li, Bin and Xiao, Sheng},
title = {A Novel ACVR2A::RAF1 Fusion in Spindle Cell Sarcoma},
journal = {Genes, Chromosomes and Cancer},
year = {2025},
volume = {64},
number = {2},
doi = {10.1002/gcc.70033}
}
EUVIMED